|
Press Releases |
|
|
|
Friday, August 25, 2023 |
|
华领医药公布2023年中期业绩 |
-- 全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(商品名:华堂宁®)于2022年9月在中国获批上市。 more info >> |
|
華領醫藥公佈2023年中期業績 |
-- 全球首創新藥葡萄糖激酶激活劑(GKA)多格列艾汀(商品名:華堂寧®)於2022年9月在中國獲批上市。 more info >> |
|
Hua Medicine Announces 2023 Interim Results |
First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
Monday, October 10, 2022 |
|
华领医药全球首创新药葡萄糖激酶激活剂华堂宁(R)获批上市 有望拓展中国2型糖尿病治疗新格局 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,公司研发的全球首创(first-in-class)新药葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片,dorzagliatin,HMS5552)已于10月8日获得中国国家药品监督管理局(NMPA)的上市批准。 more info >> |
|
華領醫藥全球首創新藥葡萄糖激酶激活劑華堂寧(R)獲批上市 有望拓展中國2型糖尿病治療新格局 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,公司研發的全球首創(first-in-class)新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片,dorzagliatin,HMS5552)已於10月8日獲得中國國家藥品監督管理局(NMPA)的上市批准。 more info >> |
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
Tuesday, June 7, 2022 |
|
华领医药在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY患者的胰岛素早相分泌和葡萄糖敏感性 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在第82届美国糖尿病协会(ADA)科学年会上,公司展示了其全球首创新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的多项临床研究成果。 more info >> |
|
華領醫藥在2022ADA科學年會公佈多格列艾汀能夠明顯改善2型糖尿病患者和GCK-MODY患者的胰島素早相分泌和葡萄糖敏感性 |
華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天宣佈,在第82屆美國糖尿病協會(ADA)科學年會上,公司展示了其全球首創新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的多項臨床研究成果。 more info >> |
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
Friday, May 13, 2022 |
|
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文 |
华领医药(“公司”,香港联交所主板股份代号:2552.HK)今日宣布,国际顶级医学刊物《自然-医学》(Nature Medicine)杂志同时在线发表了两篇公司全球首创糖尿病新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的III期注册临床研究结果的同行评议论文。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Netjoy records new high gross billing hitting RMB8.137 billion in 2023
Mar 29, 2024 12:27 HKT/SGT
|
|
|
中国生物制药(1177.HK)公布2023全年业绩
Mar 29, 2024 12:15 HKT/SGT
|
|
|
中國生物製藥(1177.HK)公布2023全年業績
Mar 29, 2024 12:09 HKT/SGT
|
|
|
Sino Biopharm (1177.HK) Announces 2023 Annual Results
Mar 29, 2024 11:45 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports FY2023 Results
Mar 29, 2024 10:15 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 29, 2024 11:00 JST
|
|
|
Fujitsu Selected as CDP Supplier Engagement Leader
Mar 29, 2024 10:28 JST
|
|
|
Mazda Production and Sales Results for February 2024
Mar 29, 2024 10:00 JST
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 06:48: JST
|
|
|
Avance Clinical은 세계 백신 대회에서 최신 백신 임상시험 뉴스를 공유합니다. 이 중에는 HIV-1 연구도 포함됩니다
Mar 29, 2024 06:42 HKT/SGT
|
|
|
Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞,包括HIV-1研究
Mar 29, 2024 06:33 HKT/SGT
|
|
|
Avance Clinical将在世界疫苗大会上分享最新的疫苗临床试验新闻,包括HIV-1研究
Mar 29, 2024 06:22 HKT/SGT
|
|
|
703-Carat L'Heure Bleu Tanzanite Carving Sets New GUINNESS WORLD RECORDS(TM) Title as World's Largest Cut Tanzanite
Mar 29, 2024 06:00 HKT/SGT
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 05:36 HKT/SGT
|
|
|
Atlas Lithium Secures US$ 30,000,000 Strategic Investment and Offtake Agreement from Mitsui
Mar 28, 2024 19:09 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|